Circulating fetuin-A in patients with pancreatic cancer: a hospital-based case-control study.
A proteomic analysis has proposed fetuin-A (alpha-2-HS-glycoprotein) as a new potential marker for pancreatic cancer (PC). Circulating fetuin-A levels in patients with PC. Serum fetuin-A was measured in 81 cases with PC and 81 matched controls before the initiation of any treatment. Serum fetuin-A was not independently associated with the presence of PC. Although there was a trend with higher fetuin-A levels across PC stages, comparisons of fetuin-A in patients within different PC prognostic stages revealed no differences. Circulating fetuin-A was similar between patients and controls and was not associated with the disease severity.